MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from public
offering of common stock,...
$4,252,245
Proceeds from loan with
related party, net of...
$3,000,000
Proceeds from issuance of
shares on atm, net of...
$86,366
Net cash provided by
financing activities
$7,284,806
Canceled cashflow
$53,805
Net (decrease)
increase in cash
-$8,333,845
Canceled cashflow
$7,284,806
Acquisition of license for
research and development
$11,909,667
Loss on debt
conversion with related...
-$6,134,120
Increase (decrease) in
accrued expenses and...
$608,290
Share-based compensation
expense
$355,642
Deferred tax expense
(benefit)
$221,096
Reduction in carrying
amount of right-of-use...
$66,115
Amortization of loan costs
$52,373
Loss on foreign
exchange
-$27,916
Loss on fixed asset
disposal
-$2,731
Depreciation
$2,063
Cash payment of
issuance costs
$53,805
Net cash used in
operating activities
-$15,618,651
Canceled cashflow
$19,380,013
Net loss
-$34,257,370
(decrease) increase in
accounts payable
-$532,607
Increase in prepaid
expenses and other...
$208,687
Back
Back
Cash Flow
source: myfinsight.com
Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. (DWTX)